The effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Wang, Qin ^a   Wang, Zhenlian ^b,c   Chu, LinYang ^d   Li, Xu ^a   Kan, Pengcheng ^a   Xin, Xin ^a   Zhu, Yu ^a   Yang, Ping ^a  

^a TIANJIN HUANHU HOSPITAL   (China)

^b CHANGZHOU UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GLUTATHIONE TRANSFERASE P1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MIR 106A; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN KINASE B; RHO FACTOR; RHOE PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN106 MICRORNA, HUMAN; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL LINE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLIOMA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; TUMOR CELL LINE;

APSEUDES; GASTROPODA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICRORNAS; QUINAZOLINES;

EID: 84929104125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125473     Document Type: Article

References (27)

1. Zhou N, Yao Y, Mao Y. The progression of children gliomas therapeutics. Journal of International Neurology and Neurosurgery. 2012; 2: 192-195. (Chinese review).
2. Cui X, Sui D, Xu C. Latest Therapy Development of Malignant Glioma. Drug Evaluation.2012; 32:27-29. (Chinese review).
3. Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013; 109:452-461. doi: 10.1038/bjc.2013.305 PMID: 23807165
4. Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res. 2015; 163:15-30. doi: 10.1007/978-3-319-12048-5-2 PMID: 25468223
5. Song Z, Yu X, He C, Zhang B, Zhang Y. Re-administration after the failure of gefitinib or erlotinib in patients with advanced glioma. J Thorac Dis. 2013; 4:400-405. doi: 10.3978/j.issn.2072-1439.2013.07.28 PMID: 23991294
6. Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, et al.Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer. 2013; 81:328-336. doi: 10.1016/j.lungcan.2013.05.020 PMID: 23809060
7. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013; 19:1114-1123. doi: 10.1038/nm.3291 PMID: 23913124
8. Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 2013; 19:3955-3965. doi: 10.1158/1078-0432.CCR-12-3302 PMID: 23719259
9. Kumar P, Luo Y, Tudela C, Alexander JM, Mendelson CR. The c-Myc-regulated microRNA-17-92 (miR-17-92) and miR-106a-363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Bio. 2013; 33:1782-1796. doi: 10.1128/MCB.01228-12 PMID: 23438603
10. Catela Ivkovic T, Aralica G, Cacev T, Loncar B, Kapitanovic S. miR-106a overexpression and pRB downregulation in sporadic colorectal cancer.Exp Mol Pathol. 2013; 94:148-154. doi: 10.1016/j.yexmp.2012.11.002 PMID: 23178825
11. Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C, et al. MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status.J Mol Med (Berl). 2011; 89:1037-1050. doi: 10.1007/s00109-011-0775-x PMID: 21656380
12. Wang Z, Wang B, Shi Y, Xu C, Xiao HL, Ma LN, et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. 2014 Apr 7. doi: 10.1038/onc.2014.75). [Epub ahead of print]
13. Zhu Y, Liu XJ, Yang P, Zhao M, Lv LX, Zhang GD, et al.Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines.Asian Pac J Cancer Prev. 2014; 7:3219-26. PMID: 24815474
14. Takakura Y, Hinoi T, Oue N, Sasada T, Kawaguchi Y, Okajima M, et al.CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. Cancer Res. 2010; 70:6767-6778. doi: 10.1158/0008-5472.CAN-09-4701 PMID: 20699370
15. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-Induced mouse model of lung adenocarcinoma. Cancer Res. 2012; 72(21): 5576-5587. doi: 10.1158/0008-5472.CAN-12-2001 PMID: 22964582
16. Feng B, Dong TT, Wang LL, Zhou HM, Zhao HC, Dong F, et al.Colorectal cancer migration and invasion initiated by microRNA-106a.PLoS One. 2012; 7:e43452. doi: 10.1371/journal.pone.0043452 PMID: 22912877
17. Jiang X, Li N. Induction of MiR-17-3p and MiR-106a by TNFα and LPS.Cell Biochem Funct. 2011; 29:164-170. doi: 10.1002/cbf.1728 PMID: 21370248
18. Liao B, Bao X, Liu L, Feng S, Zovoilis A, Liu W, et al. MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. J Biol Chem. 2013; 286:17359-17364.
19. Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y, et al. Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl-2 pathway. Mol Med Rep. 2015; 3:1951-5.
20. Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L, et al. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience. 2014; 3:205-15.
21. Wang X, Zhang H, Wang D, Li X. Association of Genetic Polymorphisms of EGFR with Glioma in a Chinese Population. Genet Test Mol Biomarkers. 2015; 1:59-62. doi: 10.1089/gtmb.2014.0228 PMID: 25514356
22. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmaco. 2011; 201:299-323. doi: 10.1007/978-3-642-14541-4-8 PMID: 21103974
23. Li K, Lu Y, Liang J, Luo G, Ren G, Wang X, et al. RhoE enhances multidrug resistance of gastric cancer cells by suppressing Bax.Biochem Biophys Res Commun. 2009; 379:212-216. doi: 10.1016/j.bbrc.2008.12.044 PMID: 19101510
24. Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG, Vaziri SA, et al. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. Leukemia. 2006; 20:1809-1818. PMID: 16932348
25. Draheim V, Reichel A, Weitschies W, Moenning U. N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci. 2010; 41:201-209. doi: 10.1016/j.ejps.2010.06.005 PMID: 20558284
26. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time? J Clin Onco. 2013; 31:1050-1060. doi: 10.1200/JCO.2012.43.0900 PMID: 23401439
27. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics. 2005; 15:523-533. PMID: 16006996